Thank you to Everyone Who Joined us for the 7th Annual Meeting Virtually or In-Person!

We held two full days of engaging and innovative sessions in San Francisco this July featuring speakers from all over the world. We're so glad you helped make this year's meeting such a great success!

View the Agenda

Groundbreaking FDA Presentation Marks Historic Moment for Testosterone Therapy

The Androgen Society made history last week as three of the field's most distinguished leaders—Dr. Mohit Khera, Dr. Marty Miner, and Dr. Abe Morgentaler—participated in a groundbreaking FDA panel that could fundamentally transform testosterone therapy access and patient care.

This pivotal panel addressed critical barriers that have long hindered optimal patient treatment, with key recommendations presented to the FDA:

Panel Recommendations:

• Eliminate the “age-related” restriction – Many medical conditions are “age-related” in that they become more prevalent with aging, including hypertension, heart disease, and most adult cancers.  These conditions are treated to improve health. The same should be true for testosterone deficiency. 
• Remove testosterone from the list of controlled substances – No other hormone is controlled. This step will reduce barriers to testosterone therapy access
• Raise treatment threshold to 350 ng/dL – Allow therapy initiation at this level when accompanied by clinical signs and symptoms
• Remove prostate cancer warnings from labeling – Reflecting current evidence and eliminating outdated concerns that prevent appropriate care

This event represents a watershed moment in our field's efforts to advance evidence-based care and remove regulatory obstacles that have prevented countless men from accessing appropriate treatment.

The Androgen Society remains committed to advocating for policies that prioritize patient health and reflect the latest scientific evidence in men’s health. 

November 2025 Newsletter Now Available

The Androgen Society is pleased to announce the release of our November 2025 Newsletter. This issue features a comprehensive Letter from the President, in-depth research summaries curated by Dr. Abdul Traish, updates on our 2026 Annual Meeting, news from our Education and Membership Committees, and highlights from our recent award recipients and Emerging Scholars cohort.

Thank you Androgen 2025 Faculty!

Welcome to the Androgen Society!

The Androgen Society is the first professional medical society dedicated entirely to testosterone deficiency (hypogonadism) and its treatment!

The Androgen Society brings together clinicians and investigators from all disciplines to share the latest research information together with clinical expertise.

The mission of the Androgen Society is to promote excellence in research, education, and clinical practice regarding testosterone deficiency and its treatment. Our vision is to provide a home for all the various disciplines involved with testosterone, including endocrinology, urology, sexual medicine, andrology, general medicine, epidemiology, and cardiology.

By sharing knowledge and ideas, we hope to propel the field forward, for the benefit of our patients, public health, and science.

We invite you to join the Androgen Society today!

To join the Androgen Society, please complete our online membership application.